Literature DB >> 15550051

Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate.

H A A M van Vliet, T A Winkel, I Noort, J Rosing, F R Rosendaal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15550051     DOI： 10.1111/j.1538-7836.2004.00983.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  6 in total

1.  Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study.

Authors:  Naomi Gronich; Idit Lavi; Gad Rennert
Journal:  CMAJ       Date:  2011-11-07       Impact factor: 8.262

2.  Arterial thrombosis and drospirenone-containing pill (Yasmin). Is the pill to be absolutely avoided by women who smoke?

Authors:  Antonio Girolami; Fabiana Tezza; Emanuele Allemand; Bruno Girolami
Journal:  J Thromb Thrombolysis       Date:  2007-12-23       Impact factor: 2.300

3.  Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database.

Authors:  Lianne Parkin; Katrina Sharples; Rohini K Hernandez; Susan S Jick
Journal:  BMJ       Date:  2011-04-21

4.  Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study.

Authors:  Heiko Rühl; Lars Schröder; Jens Müller; Shorena Sukhitashvili; Julia Welz; Walther C Kuhn; Johannes Oldenburg; Christian Rudlowski; Bernd Pötzsch
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

5.  The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.

Authors:  A van Hylckama Vlieg; F M Helmerhorst; J P Vandenbroucke; C J M Doggen; F R Rosendaal
Journal:  BMJ       Date:  2009-08-13

Review 6.  Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk.

Authors:  Laure Morimont; Hélène Haguet; Jean-Michel Dogné; Ulysse Gaspard; Jonathan Douxfils
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-09       Impact factor: 5.555
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.